CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Methotrexate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03520842
NCT03520842Phase 2Completed
CompareCT.gov

Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)

Stanford University·interventional·Posted May 11, 2018·Updated Aug 1, 2023

In Brief

A Phase 2 clinical trial evaluating Methotrexate, Pharmacokinetic Study, and 1 other intervention for KRAS Gene Mutation and 3 related conditions. Completed, enrolled 22 participants across 1 site.

Detailed Summary

This phase II trial studies how well regorafenib works together with methotrexate in treating participants with metastatic non-squamous non-small cell lung cancer with tumors that harbor a KRAS mutation. Regorafenib is a targeted therapy that works on different cancer pathways to stop the growth of tumor cells and stop them from spreading. Methotrexate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving regorafenib and methotrexate together may work in treating participants with KRAS mutated non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 11, 2018
Enrollment StartAug 14, 2018
Primary CompletionJun 15, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 8.1 years ago

Interventions

Methotrexatedrug

Given PO

Pharmacokinetic Studyother

Correlative studies

Regorafenibdrug

Given PO